Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 5A pseudogene 4 (EIF5AP4) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a known protein-coding gene (EIF5A), but is typically nonfunctional due to accumulated mutations. Pseudogenes are generally not translated into proteins and do not encode functional receptors, enzymes, transporters, or other classical therapeutic targets. The EIF5AP4 gene, previously also known as EIF5AL3, is annotated in human genome databases but there is no evidence in the literature that it functions as a conventional therapeutic target, contributes to biological processes, plays a role in disease, interacts with drugs, or serves as a biomarker. Its designation as a pseudogene implies it is not directly involved in translation, signal transduction, cell cycle, or other key cellular functions—those roles belong to its parent gene, EIF5A. While some pseudogenes can have regulatory roles (e.g., as competing endogenous RNAs or miRNA decoys), there is no published evidence that EIF5AP4 has such functions[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 5A pseudogene 4 (EIF5AP4).